This study consists of Part A and Part B. Part A is a multi-center, randomized, double-blind,
placebo-controlled clinical study to assess the safety, efficacy, PK and immunogenicity of
RBD1016 injection combined with NAs in CHB participants. Part B is a multi-center, open
clinical study to assess the safety, efficacy, PK and immunogenicity of RBD1016 injection
combined with PegIFN-α and NAs in CHB participants.